Regional Harmonisation and Reliance Pathways for Ethiopian Medical Devices

1. Key takeaways

Ethiopia’s position in regional regulatory convergence can be summarised as one first and one gap. The first: it is the first country in the Intergovernmental Authority on Development (IGAD) region to reach WHO medicines regulatory maturity level 3, and the ninth in Africa. The gap: the substantive outcomes of regional cooperation currently concentrate on the medicines side, and the device side has not yet produced a reliance mechanism that can be depended upon. What companies can leverage today is document reuse and pathway analogy, not cross-border automatic recognition of approvals. Planning submissions around an expectation that an approval in one country will shorten review in another is therefore unsafe for devices, while planning dossiers in a structure that travels across markets is both safe and inexpensive, and remains valuable whichever way the regional machinery eventually develops. The sections below separate what the official texts actually provide from what the regional headlines suggest, so that reliance decisions rest on documents rather than on impressions.

2. Legal basis

3. Expert insights

Insight 1: the regional convergence tool actually available in Ethiopia is reliance, not mutual recognition.

The reliance pathways listed in Section 9.4 of EFDA-GDL-046 accept approvals from 8 stringent regulatory authorities (SRAs) as well as WHO PQ and UNFPA PQ listings as evidence. This is unilateral reliance: EFDA decides on its own which external evidence to accept, and no consent from the other country is required. Mutual recognition between states, by contrast, is a bilateral or multilateral arrangement. The two differ completely in legal nature and in maturity, and confusing them leads companies to overestimate the speed benefits available today.

Insight 2: the public reference to 8 ML3 countries recognising each other points to medicines and should not be extrapolated to devices.

In public reporting, the EFDA Director-General noted that 8 ML3 countries have signed agreements to mutually recognise each other’s decisions. That statement was made in a medicines regulatory context, since the ML3 rating applies to medicines. Device-side mutual recognition across Africa remains at a building stage, and it should not be treated as a basis for submission pathways at present, whatever its eventual promise may be.

Insight 3: the value of being first in IGAD lies in demonstration, not in a channel.

As the first ML3 country in the IGAD region, Ethiopia’s regulatory conclusions carry demonstration significance within the region and can support its products entering neighbouring markets. Looked at from the other direction, however, approvals granted by neighbouring countries are not automatically recognised in Ethiopia on that account. The demonstration effect builds reputation and policy attention; it does not build an expedited approval lane.

Insight 4: AfCFTA and COMESA provide trade and industrial frameworks, not a substitute for review.

Public reporting cites Ethiopia’s locational opportunities under the African Continental Free Trade Area (AfCFTA) and the Common Market for Eastern and Southern Africa (COMESA). These frameworks address tariffs and facilitation of market access; the marketing authorisation of a product must still be obtained country by country. Investment cases built on trade frameworks should therefore carry separate regulatory budgets and timelines for each target market.

Insight 5: localisation will be the real amplifier of regional convergence.

With the local production share rising from 8% to 44%, and with the regional credibility that ML3 brings, the structure of producing in Ethiopia and exporting to the region fits the policy direction better than exporting from the Chinese mainland to Ethiopia. For manufacturers with a long-term African footprint this is an option worth quantifying, since it converts a compliance obligation into a commercial position.

4. Practical recommendations

1. Use the reliance pathway first: check whether the product already holds an SRA approval or a WHO PQ/UNFPA PQ listing, the only cross-border evidence mechanism with an explicit official text today.
2. Do not write mutual recognition into project plans: with no device-side mechanism in place, schedule submissions and budgets country by country.
3. Build documents, not decisions: prepare dossiers in a unified structure, such as the six chapters of EFDA/GDL/097 Version 002, so they can be reused across markets.
4. Follow regional organisation developments: device-related progress in the AU, IGAD, COMESA and AfCFTA is worth tracking, but should not be booked in advance.
5. Quantify localisation if the horizon is long: weigh rising local production shares and regional export potential when assessing local assembly or partnership.
6. Separate trade facilitation from technical review: the conveniences created by regional frameworks do not replace the marketing authorisation.

5. Verification checklist

• □ Reliance pathway (Section 9.4) confirmed as the cross-border evidence mechanism currently available
• □ SRA list and WHO PQ/UNFPA PQ listings checked against the current published version
• □ Project plan does not depend on device-side regional mutual recognition
• □ Dossier structure organised for reuse across multiple countries
• □ Medicines-side ML3 recognition distinguished from the device-side status quo
• □ Tracking mechanism for regional organisation developments in place
• □ Feasibility of local production assessed where applicable

Regulatory information verified as of 29 October 2026. The regional convergence content listed in this article follows EFDA official announcements, public statements by the Ethiopian Ministry of Health, the World Bank feature and the current text of Section 9.4 of EFDA-GDL-046; regional mechanisms move quickly, so official originals must be checked before citation.

• Local resource in Ethiopia: GRZAN assists manufacturers from the Chinese mainland and overseas in engaging the Ethiopian Food and Drug Authority (EFDA) on marketing authorisation (MA), Certificate of Competency (CoC) and import licence applications, including local representative structuring and agreement review, SRA reliance rationales, UMDN coding and classification, technical documentation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorisation applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles compliance arguments, labelling and instructions-for-use localisation (English), and vigilance reporting with field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.